セフォキシチン
セフォキシチン 物理性質(zhì)
- 融點 :
- 149-150℃
- 沸點 :
- 843℃
- 比重(密度) :
- 1.4441 (rough estimate)
- 屈折率 :
- 1.6390 (estimate)
- RTECS 番號:
- XI0386500
- 閃點 :
- >110°(230°F)
- 貯蔵溫度 :
- 2-8°C
- 溶解性:
- DMSO（微量）、メタノール（微量）
- 外見 :
- 個體
- 酸解離定數(shù)(Pka):
- 2.2(at 25℃)
- 色:
- ホワイトからオフホワイト
- 水溶解度 :
- 予測される水への溶解度は 0.2mg/ml 未満
- InChIKey:
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
- SMILES:
- N12[C@@]([H])([C@](OC)(NC(CC3SC=CC=3)=O)C1=O)SCC(COC(N)=O)=C2C(O)=O
- CAS データベース:
- 35607-66-0(CAS DataBase Reference)
- EPAの化學(xué)物質(zhì)情報:
- Cefoxitin (35607-66-0)
安全性情報
- リスクと安全性に関する聲明
- 危険有害性情報のコード(GHS)
| RIDADR |
3077 |
|
|
| 國連危険物分類 |
9 |
|
|
| 容器等級 |
III |
|
|
| HSコード |
30032013 |
|
|
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
區(qū)分 |
注意喚起語 |
シンボル |
P コード |
| H317 |
アレルギー性皮膚反応を起こすおそれ |
感作性、皮膚 |
1 |
警告 |
|
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
|
| 注意書き |
| P261 |
粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。 |
| P321 |
特別な処置が必要である（このラベルの．．． を見よ）。 |
| P333+P313 |
皮膚刺激または発疹が生じた場合：醫(yī)師の診斷/手當(dāng)てを 受けること。 |
|
| メーカー |
製品番號 |
製品説明 |
CAS番號 |
包裝 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01COBQC-6999 |
セホキシチン
Cefoxitin |
35607-66-0 |
1g |
￥12500 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01COBQC-6999 |
セホキシチン
Cefoxitin |
35607-66-0 |
5g |
￥30000 |
2024-03-01 |
購入 |
|
東京化成工業(yè)
|
C3598 |
セフォキシチン >98.0%(HPLC)
Cefoxitin
>98.0%(HPLC) |
35607-66-0 |
1g |
￥12600 |
2024-03-01 |
購入 |
|
東京化成工業(yè)
|
C3598 |
セフォキシチン >98.0%(HPLC)
Cefoxitin
>98.0%(HPLC) |
35607-66-0 |
5g |
￥42200 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01COBQC-6999 |
セホキシチン
Cefoxitin |
35607-66-0 |
10g |
￥50000 |
2024-03-01 |
購入 |
セフォキシチン 化學(xué)特性,用途語,生産方法
外観
白色～ほとんど白色粉末～結(jié)晶
効能
抗生物質(zhì), 細(xì)胞壁合成阻害薬
説明
Cefoxitin contains the same C-7 side chain as cephalothin and the same C-3 side chain as cefuroxime. The
most novel chemical feature of cefoxitin is the possession of an α-oriented methoxyl group in place of the
normal H-atom at C-7. This increased steric bulk conveys very significant stability against β-lactamases. The
inspiration for these functional groups was provided by the discovery of the naturally occurring antibiotic
cephamycin C
derived from fermentation of Streptomyces lactamdurans. Cephamycin C itself has not seen clinical use but,
rather, has provided the structural clue that led to useful agents such as cefoxitin. Agents that contain this
7α methoxy group are commonly referred to as cephamycins. Ingenious chemical transformations now enable
synthetic introduction of such a methoxy group into cephalosporins lacking this feature.
使用
Cefoxitinis a semisynthetic, broad-spectrum second-generation cephalosporin with antibacterial activity. The activity of cefoxitin results in the weakening of the bacterial cell wall and causes cell lysis. Cefoxitin acts by interfering with cell wall synthesis. Its activity spectrum includes a broad range of gram-negative and gram-positive bacteria including anaerobes.
抗菌性
Most Gram-positive bacilli are susceptible, but L. monocytogenes is resistant. It is resistant to many Gramnegative
β-lactamases and is active against organisms elaborating
them, including some Citrobacter, Providencia, Serratia
and Acinetobacter spp. Enterobacter spp. are resistant. It is moderately
active against Bacteroides spp., but considerable strain
variation in susceptibility occurs.
獲得抵抗性
Resistant strains of Bacteroides, some of which produce
β-lactamases that hydrolyze cefoxitin, have been described.
Resistance may be transferable to other Bacteroides spp. It is a
potent inducer of chromosomal cephalosporinases of certain
Gram-negative bacilli and can antagonize the effect
of cefotaxime and other β-lactam agents.
臨床応用
As for other group 3 cephalosporins, with particular emphasis
on mixed infections including anaerobes, notably abdominal
and pelvic sepsis. In considering its use, its low activity against
aerobic Gram-positive cocci should be noted.
副作用
Reactions are those common to cephalosporins. Pain on
intramuscular, and thrombophlebitis on intravenous, injection
occur. Substantial changes can occur in the fecal flora,
with virtual eradication of susceptible enterobacteria and
non-
fragilis Bacteroides, and appearance of, or increase in,
yeasts, enterococci and other resistant bacteria including
C. difficile. Development of meningitis due to H. influenzae and
Str. pneumoniae in patients treated for other infections has been
observed.
セフォキシチン 上流と下流の製品情報
原材料
準(zhǔn)備製品
セフォキシチン 生産企業(yè)
Global( 279)Suppliers
35607-66-0(セフォキシチン)キーワード:
- 35607-66-0
- (6r-cis)-ethyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)
- cephoxitin
- CEFOXITIN
- Mefoxin
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-, (6R,7S)-
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-, (6R-cis)-
- (6R-cis)-3-[(Carbamoyloxy)methyl]-7-methoxy-8-oxo-7-(2-thienylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[[2-(2-thienyl)acetyl]amino]-, (6R,7S)-
- Rephoxitin
- (6R,7S)-3-(Carbamoyloxymethyl)-7β-methoxy-8-oxo-7-[(2-thienyl)acetylamino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- C06887
- Cefoxitin (500 mg)
- Bisoprolol FuMarate IMpurity-J
- (6R,7S)-3-[(carbaMoyloxy)Methyl]-7-Methoxy-8-oxo-7-[2-(thiophen-2-yl)acetaMido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- Cefoxitin Solution, 100ppm
- Cefoxitin(Mefoxin)
- Cefoxitin【(6R-cis)-3-[(Carbamoyloxy)methyl]-7-methoxy-8-oxo-7-(2-thienylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid】
- (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(1-oxo-2-thiophen-2-ylethyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- Cefoxitin Cefoxitin
- Cefoxitin USP/EP/BP
- Cefoxitin (1098107)
- Cefoxitinum
- Cefotaxidine
- Cefoxitin for peak identification A CRS
- Cefoxitinic acid
- (6R,7S)-3-[(Carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[2-(thien-2-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- cfx
- CEFOXITIN ACID
- (7S)-7-[(2-テニルカルボニル)アミノ]-7-メトキシ-3-[(カルバモイルオキシ)メチル]セファム-3-エン-4-カルボン酸
- (6R,7S)-3-(カルバモイルオキシメチル)-7β-メトキシ-8-オキソ-7-[(2-チエニル)アセチルアミノ]-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸
- セフォキシチン
- セホキシチン
- (6R,7S)-3-[(カルバモイルオキシ)メチル]-7-メトキシ-8-オキソ-7-[2-(チオフェン-2-イル)アセトアミド]-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸
- セファロスポリン類